Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Literature Evidence and ARRIVE Assessment on Neuroprotective Effects of Flavonols in Neurodegenerative Diseases' Models.

Bombardi Duarte AC, Santana MG, di Camilo Orfali G, de Oliveira CTP, Priolli DG.

CNS Neurol Disord Drug Targets. 2018 Apr 26;17(1):34-42. doi: 10.2174/1871527317666171221110139. Review.

PMID:
29268692
2.

Neuroprotective actions of flavones and flavonols: mechanisms and relationship to flavonoid structural features.

Dajas F, Andrés AC, Florencia A, Carolina E, Felicia RM.

Cent Nerv Syst Agents Med Chem. 2013 Mar;13(1):30-5. Review.

PMID:
23092407
3.

Neuroprotection of Coenzyme Q10 in Neurodegenerative Diseases.

Yang X, Zhang Y, Xu H, Luo X, Yu J, Liu J, Chang RC.

Curr Top Med Chem. 2016;16(8):858-66. Review.

PMID:
26311425
4.

Hesperidin as a Neuroprotective Agent: A Review of Animal and Clinical Evidence.

Hajialyani M, Hosein Farzaei M, Echeverría J, Nabavi SM, Uriarte E, Sobarzo-Sánchez E.

Molecules. 2019 Feb 12;24(3). pii: E648. doi: 10.3390/molecules24030648. Review.

5.

PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease.

Corona JC, Duchen MR.

Free Radic Biol Med. 2016 Nov;100:153-163. doi: 10.1016/j.freeradbiomed.2016.06.023. Epub 2016 Jun 25. Review.

6.

Neurodegenerative diseases: From available treatments to prospective herbal therapy.

Solanki I, Parihar P, Parihar MS.

Neurochem Int. 2016 May;95:100-8. doi: 10.1016/j.neuint.2015.11.001. Epub 2015 Nov 10. Review.

PMID:
26550708
7.

Flavonoid-based therapies in the early management of neurodegenerative diseases.

Solanki I, Parihar P, Mansuri ML, Parihar MS.

Adv Nutr. 2015 Jan 15;6(1):64-72. doi: 10.3945/an.114.007500. Print 2015 Jan. Review.

8.

Review of anticancer mechanisms of isoquercitin.

Orfali Gd, Duarte AC, Bonadio V, Martinez NP, de Araújo ME, Priviero FB, Carvalho PO, Priolli DG.

World J Clin Oncol. 2016 Apr 10;7(2):189-99. doi: 10.5306/wjco.v7.i2.189. Review.

9.

Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.

Dunkel P, Chai CL, Sperlágh B, Huleatt PB, Mátyus P.

Expert Opin Investig Drugs. 2012 Sep;21(9):1267-308. doi: 10.1517/13543784.2012.703178. Epub 2012 Jun 28. Review.

PMID:
22741814
10.

Beneficial Effects of Flavonoids Against Parkinson's Disease.

Jung UJ, Kim SR.

J Med Food. 2018 May;21(5):421-432. doi: 10.1089/jmf.2017.4078. Epub 2018 Feb 7. Review.

PMID:
29412767
11.

Protective effects of quercetin glycosides, rutin, and isoquercetrin against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity in rat pheochromocytoma (PC-12) cells.

Magalingam KB, Radhakrishnan A, Haleagrahara N.

Int J Immunopathol Pharmacol. 2016 Mar;29(1):30-9. doi: 10.1177/0394632015613039. Epub 2015 Nov 5.

12.

Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway.

Mandel SA, Avramovich-Tirosh Y, Reznichenko L, Zheng H, Weinreb O, Amit T, Youdim MB.

Neurosignals. 2005;14(1-2):46-60. Review.

13.

The neuroprotective effects of caffeine in neurodegenerative diseases.

Kolahdouzan M, Hamadeh MJ.

CNS Neurosci Ther. 2017 Apr;23(4):272-290. doi: 10.1111/cns.12684. Review.

14.

Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders.

Forlenza OV, De-Paula VJ, Diniz BS.

ACS Chem Neurosci. 2014 Jun 18;5(6):443-50. doi: 10.1021/cn5000309. Epub 2014 May 6. Review.

15.

Lipophilic antioxidants in neurodegenerative diseases.

Chang KH, Cheng ML, Chiang MC, Chen CM.

Clin Chim Acta. 2018 Oct;485:79-87. doi: 10.1016/j.cca.2018.06.031. Epub 2018 Jun 22. Review.

PMID:
29940147
16.

Phytochemical treatments target kynurenine pathway induced oxidative stress.

Parasram K.

Redox Rep. 2018 Dec;23(1):25-28. doi: 10.1080/13510002.2017.1343223. Epub 2017 Jun 26. Review.

PMID:
28651456
17.

Curcumin and neurodegenerative diseases: a perspective.

Darvesh AS, Carroll RT, Bishayee A, Novotny NA, Geldenhuys WJ, Van der Schyf CJ.

Expert Opin Investig Drugs. 2012 Aug;21(8):1123-40. doi: 10.1517/13543784.2012.693479. Epub 2012 Jun 6. Review.

PMID:
22668065
18.

Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.

Lauterbach EC, Victoroff J, Coburn KL, Shillcutt SD, Doonan SM, Mendez MF.

J Neuropsychiatry Clin Neurosci. 2010 Winter;22(1):8-18. doi: 10.1176/appi.neuropsych.22.1.8. Review.

PMID:
20160205
19.

Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design.

Sehgal SA, Hammad MA, Tahir RA, Akram HN, Ahmad F.

Curr Neuropharmacol. 2018;16(6):649-663. doi: 10.2174/1570159X16666180315142137. Review.

20.

Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases.

Asanuma M, Miyazaki I, Ogawa N.

Curr Pharm Des. 2004;10(6):695-700. Review.

PMID:
14965332

Supplemental Content

Support Center